Partner Fred Geilfuss and Special Counsel Kyle Faget were quoted in a Modern Healthcare article, “ACA repeal wouldn’t stop transition to value-based payment, efforts to lower drug spending,” about what would happen if the Affordable Care Act is ultimately held to be unconstitutional.
Geilfuss said providers that have already invested in the infrastructure, technology and staff to facilitate new payment models like accountable care organizations, bundled payments and Medicare Shared Savings would probably continue to do so. “To just throw that out seems very unlikely,” he said. “There would be a lot of people who are motivated to figure out a way to continue that momentum.”
Faget said if the ACA is found to be unconstitutional, Congress would probably reenact the Biologics Price Competition and Innovation Act of 2009, which was folded into the ACA, as a standalone law. The act allows the Food and Drug Administration to approve biosimilars, which mimic expensive biologic drugs made from living organisms. “Biosimilars are absolutely a big part of reducing drug prices,” she said.
Geilfuss said providers that have already invested in the infrastructure, technology and staff to facilitate new payment models like accountable care organizations, bundled payments and Medicare Shared Savings would probably continue to do so. “To just throw that out seems very unlikely,” he said. “There would be a lot of people who are motivated to figure out a way to continue that momentum.”
Faget said if the ACA is found to be unconstitutional, Congress would probably reenact the Biologics Price Competition and Innovation Act of 2009, which was folded into the ACA, as a standalone law. The act allows the Food and Drug Administration to approve biosimilars, which mimic expensive biologic drugs made from living organisms. “Biosimilars are absolutely a big part of reducing drug prices,” she said.
People
Related News
17 April 2024
In the News
Steven Barth on Allure of Take-Private Deals – 'Public markets aren’t what they’re cracked up to be'
Foley & Lardner LLP partner Steven Barth offers extensive insight on the growing trend of family-owned consumer and retail businesses aiming to go private in the Axios article, “Family-owned companies see allure in take-private deals.”
16 April 2024
In the News
Claire Marblestone Assesses Increased Scrutiny of CA Health Care Transactions
Foley & Lardner LLP partner Claire Marblestone is quoted in the Law360 article, “Struggling Hospitals Seek Mergers As Regulators Push Back.”
15 April 2024
In the News
Nathaniel Lacktman Joins Double Take by Newton Podcast to Talk Telemedicine
Foley & Lardner LLP Nathaniel Lacktman appeared on Newton Investment Management’s Double Take by Newton podcast episode “Modernizing Medicine” to discuss the health care industry’s digital evolution and the benefits of telemedicine.